Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GOSS Gossamer Bio Inc
- Stocks
- Healthcare
- NASDAQ: GOSS
Price (delayed)
$1.25
Market cap
$284.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.23
Enterprise value
$457.04M
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an
Highlights
GOSS's EPS has soared by 77% year-on-year and by 8% since the previous quarter
Gossamer Bio's net income has soared by 70% YoY and by 9% from the previous quarter
GOSS's equity has shrunk by 123% YoY and by 121% QoQ
The quick ratio is down by 20% year-on-year and by 18% since the previous quarter
Key stats
What are the main financial stats of GOSS
Market
Valuations
Earnings
Shares outstanding
227.3M
Market cap
$284.13M
Enterprise value
$457.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.67
Revenue
$124.59M
Gross profit
$124.59M
Operating income
-$54.77M
Net income
-$51.24M
EBIT
-$39.21M
EBITDA
-$35.7M
Free cash flow
$9.08M
Per share
Balance sheet
Liquidity
EPS
-$0.23
EPS diluted
-$0.23
Free cash flow per share
$0.04
Book value per share
-$0.03
Revenue per share
$0.55
TBVPS
$1.24
Total assets
$280.59M
Total liabilities
$286.84M
Debt
$201.93M
Equity
-$6.25M
Working capital
$227.25M
Debt to equity
-32.31
Current ratio
5.71
Quick ratio
5.49
Net debt/EBITDA
-4.84
Margins
Efficiency
Dividend
EBITDA margin
-28.7%
Gross margin
100%
Net margin
-41.1%
Operating margin
-44%
Return on assets
-15.5%
Return on equity
-129%
Return on invested capital
-9%
Return on capital employed
-16.9%
Return on sales
-31.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GOSS stock price
How has the Gossamer Bio stock price performed over time
Intraday
1.63%
1 week
-9.42%
1 month
12.61%
1 year
31.91%
YTD
38.18%
QTD
1.63%
Financial performance
How have Gossamer Bio's revenue and profit performed over time
Revenue
$124.59M
Gross profit
$124.59M
Operating income
-$54.77M
Net income
-$51.24M
Gross margin
100%
Net margin
-41.1%
Gossamer Bio's net income has soared by 70% YoY and by 9% from the previous quarter
Gossamer Bio's operating income has surged by 69% YoY and by 9% QoQ
The net margin rose by 17% since the previous quarter
The operating margin is up by 16% since the previous quarter
Price vs fundamentals
How does GOSS's price correlate with its fundamentals
Growth
What is Gossamer Bio's growth rate over time
Valuation
What is Gossamer Bio stock price valuation
P/E
N/A
P/B
N/A
P/S
2.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.67
GOSS's EPS has soared by 77% year-on-year and by 8% since the previous quarter
GOSS's equity has shrunk by 123% YoY and by 121% QoQ
GOSS's price to sales (P/S) is 12% higher than its last 4 quarters average of 2.0
GOSS's revenue is up by 9% QoQ
Efficiency
How efficient is Gossamer Bio business performance
Gossamer Bio's ROIC has soared by 78% YoY and by 12% from the previous quarter
The company's return on equity has surged by 75% YoY but it fell by 10% QoQ
GOSS's ROA has soared by 75% year-on-year and by 11% since the previous quarter
GOSS's ROS is up by 18% since the previous quarter
Dividends
What is GOSS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GOSS.
Financial health
How did Gossamer Bio financials performed over time
GOSS's total assets is 2.2% lower than its total liabilities
The total liabilities is up by 23% year-on-year
The current ratio has contracted by 20% YoY and by 17% from the previous quarter
GOSS's equity has shrunk by 123% YoY and by 121% QoQ
The debt has declined by 2.2% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.